Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis

Department of Oncology, APHP, Hôpital Avicenne, Bobigny, France.
European journal of cancer (Oxford, England: 1990) (Impact Factor: 4.82). 06/2009; 45(10):1890-6. DOI: 10.1016/j.ejca.2009.04.018
Source: PubMed

ABSTRACT Microsatellite instability (MSI) status in predicting the efficacy of adjuvant chemotherapy in colorectal cancer remains controversial.
Studies were identified through PubMed, Embase and ASCO proceedings with a combination of keywords (colorectal cancer, chemotherapy and MSI).
A MA was performed for treated and non-treated MSI population on seven studies. Statistical calculations were performed on 7 studies representing 3690 patients; mean age: 65.5 years; 810 stage II and 2444 stage III (75%). MSI-high (MSI-H) was found in 454 patients (14% of the global population), and microsatellite stable (MSS) in 2871. A total of 1444 patients received 5-fluorouracil (5FU)-based chemotherapy, whereas 1518 patients did not. For MSI-H patients, there was no statistically significant difference for RFS whether or not they received chemotherapy (5 studies); HR RFS: 0.96 (95% confidence interval (CI): 0.62-1.49); HR OS (6 studies): 0.70 (95% CI: 0.44-1.09; p=0.12). Elsewhere, we found a significant interaction between MSI status (MSI-H or MSS) and therapeutic status suggesting a lesser benefit for MSI-H than for MSS patients (HR interaction RFS: 0.77 (95% CI: 0.67-0.87)).
We found similar RFS for treated and untreated MSI-H patients, showing that MSI-H status, in addition to being a good prognostic factor is also a predictive factor of non response.

Download full-text


Available from: Gerard Yves Perret, Jul 20, 2015
1 Follower
  • Source
    • "Cost-effectiveness data suggest IHC is a better first step because targeted DNA testing can be peformed based on IHC findings. However, there is also the argument that MSI-high (MSI-H) tumors may be less reponsive to 5FU, thus providing additional treatment information (Des Guetz et al. 2009; Sinicrope and Sargent 2009). The high concordance between absent protein staining by IHC and a MSI-H pattern in colorectal tumors allows for either method to be a reasonable approach (Palomaki et al. 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: An electronic survey of the National Society of Genetic Counselors Cancer Special Interest Group was conducted in July 2011 to assess Lynch syndrome tumor screening programs and identify barriers to implementation. Over half of respondents (52.8 %) reported having a routine Lynch syndrome tumor screening protocol for newly diagnosed colon and/or endometrial cancers, and approximately half of these used a universal approach. There was an increase in the number of those screening over time, especially in the past 3 years. Tumor screening methods varied; 34/53 (64.2 %) started with immunohistochemistry, 11/53 (20.8 %) started with microsatellite instability testing and 8/53 (15.1 %) performed both on newly diagnosed colorectal tumors. Just 21.7 % (23/106) of respondents indicated they have a tumor screening program in place for newly diagnosed endometrial cancers. Written consent is rarely obtained (7.1 %) and the method of how results were returned to the patient was variable among respondents. Prevalent barriers to implementation were concern about cost, bringing key players together and convincing medical staff of the necessity. Use of Lynch syndrome tumor screening is in clinical practice, but protocols vary widely. This survey provides a glimpse of current practices and common barriers, and identifies the need for tumor screening algorithms with outcomes data.
    Journal of Genetic Counseling 05/2013; 23(1). DOI:10.1007/s10897-013-9603-5 · 1.75 Impact Factor
  • Source
    • "Adjuvant chemotherapy setting 7/3690 454/14,0 % MSI-H a negative predictive factor in adjuvant setting DesGuetz et al. (2009) Metastatic chemotherapy setting 6/964 91/9,4 % MSI-H a positive prognostic factor. No clear conclusion concerning MSI-H as a predictive factor Guastadisegni et al. (2010) 31/12872 1972/15,4 % MSI-H a positive prognostic factor. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Colorectal cancer (CRC) is the third most common cancer in the world. In 75% CRC develops sporadically, in 25% hereditary or as a consequence of inflammatory bowel disease. CRC carcinogenesis develops over many years. The cause of CRC in 85% is chromosomal instability (CIN) and in 15% microsatellite instability (MSI-H), where hereditary nonpolyposis colorectal cancer (HNPCC) represents 10–20%. Microsatellite sequences (MS) are repeated sequences of short stretches of DNA all over the genome. Microsatellite stability (MSS) means MS are the same in each cell of an individual, whereas microsatellite instability (MSI-H) means MS differ in normal and cancer cells of an individual. The cause of MSI-H is a damaged mismatch repair mechanism (MMR), with the most important MMR proteins being MSH2, MLH1 and MSH6. Conclusions MSI-H seems to be an important prognostic factor in CRC and an important predictive factor of CRC chemotherapeutic treatment efficacy. Clinical trials conducted until now have shown contradictory findings in different chemotherapeutic settings, adjuvant and palliative; therefore MSI-H is going to be the object of the future research. The future of cancer treatment is in the individualized therapy based on molecular characteristics of the tumour, such as MSI-H in CRC.
    Radiology and Oncology 06/2011; 45(2):75-81. DOI:10.2478/v10019-011-0005-8 · 1.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Diagnostik in der Pathologie leistet heute einen wesentlichen Beitrag zur individualisierten Therapie des Dickdarmkarzinoms. Als Standardmethode kann der molekularpathologische Nachweis einer KRAS-Mutation das Nichtansprechen auf die Anti-EGFR-Antikörper-Therapie vorhersagen. Die Erkennung eines Mismatch-Reparatur-Defekts oder der damit verbundenen hochgradigen Mikrosatelliteninstabilität indiziert eine Resistenz gegen die 5-FU-Monotherapie. Zudem zeigen der Nachweis von hochgradiger Mikrosatelliteninstabilität und hiermit assoziierte Subtypen des Dickdarmkarzinoms, wie das medulläre Karzinom, ein niedriges Fernmetastasierungsrisiko und damit eine geringe Notwendigkeit für eine adjuvante Chemotherapie an. Pathological diagnosis is essential today for the individualized therapy of colorectal cancer. In the routine analysis of colorectal carcinomas the molecular-pathological detection of a KRAS mutation predicts unresponsiveness to EGFR-targeted antibody therapies. Moreover, the detection of mismatch-repair deficiency or high-degree microsatellite instability indicates unresponsiveness to 5-FU monotherapy. Colorectal carcinomas with high-grade microsatellite instability and their associated morphologic subtypes, such as the medullary carcinoma, exhibit a low risk of distant metastasis and might be considered as carcinomas with low need for adjuvant chemotherapy. SchlüsselwörterDickdarmkarzinom-Individualisierte Therapie-KRAS-Mikrosatelliteninstabilität KeywordsColorectal cancer-Individualized therapy-KRAS-Microsatellite instability
    Der Pathologe 02/2009; 31(1):16-21. DOI:10.1007/s00292-009-1240-2 · 0.64 Impact Factor
Show more

Similar Publications